Estimated costs of hospitalization due to coronary artery disease attributable to familial hypercholesterolemia in the Brazilian public health system
dc.contributor.author | Bahia, Luciana Ribeiro | pt_BR |
dc.contributor.author | Rosa, Roger dos Santos | pt_BR |
dc.contributor.author | Santos Filho, Raul Dias dos | pt_BR |
dc.contributor.author | Araújo, Denizar Vianna | pt_BR |
dc.date.accessioned | 2018-09-19T02:32:39Z | pt_BR |
dc.date.issued | 2018 | pt_BR |
dc.identifier.issn | 2359-4292 | pt_BR |
dc.identifier.uri | http://hdl.handle.net/10183/182153 | pt_BR |
dc.description.abstract | Cardiovascular diseases are the leading cause of death in Brazil, imposing substantial economic burden on the health care system. Familial hypercholesterolemia (FH) is known to greatly increase the risk of premature coronary artery disease (CAD). This study aimed to estimate the economic impact of hospitalizations due to CAD attributable to FH in the Brazilian Unified Health Care System (SUS). Subjects and methods: Retrospective, cross-sectional study of data obtained from the Hospital Information System of the SUS (SIHSUS). We selected all adults (≥ 20 years of age) hospitalized from 2012- 2014 with primary diagnoses related to CAD (ICD-10 I20 to I25). Attributable risk methodology estimated the contribution of FH in the outcomes of interest, using international data for prevalence (0.4% and 0.73%) and relative risk for events (RR = 8.56). Results: Assuming an international prevalence of FH of 0.4% and 0.73%, of the 245,981 CAD admissions/year in Brazil, approximately 7,249 and 12,915, respectively, would be attributable to an underlying diagnosis of FH. The total cost due to CAD per year, considering both sexes and all adults, was R$ 985,919,064, of which R$ 29,053,500 and R$ 51,764,175, respectively, were estimated to be attributable to FH. The average cost per FH-related CAD event was R$ 4,008. Conclusion: Based on estimated costs of hospitalization for CAD, we estimated that 2.9-5.3% are directed to FH patients. FH can require early specific therapies to lower risk in families. It is mandatory to determine the prevalence of FH and institute appropriate treatment to minimize the clinical and economic impact of this disease in Brazil. | en |
dc.format.mimetype | application/pdf | pt_BR |
dc.language.iso | eng | pt_BR |
dc.relation.ispartof | Archives of endocrinology and metabolism. São Paulo. Vol. 62, no. 3 (May/June 2018), p. 303-308. | pt_BR |
dc.rights | Open Access | en |
dc.subject | Costs and cost analysis | en |
dc.subject | Doença da artéria coronariana | pt_BR |
dc.subject | Hospitalização | pt_BR |
dc.subject | coronary artery disease | en |
dc.subject | Familial hypercholesterolemia | en |
dc.subject | Custos e análise de custo | pt_BR |
dc.subject | Sistema Único de Saúde | pt_BR |
dc.subject | Brazil | en |
dc.subject | Brasil | pt_BR |
dc.subject | Hospitalization | en |
dc.title | Estimated costs of hospitalization due to coronary artery disease attributable to familial hypercholesterolemia in the Brazilian public health system | pt_BR |
dc.type | Artigo de periódico | pt_BR |
dc.identifier.nrb | 001073274 | pt_BR |
dc.type.origin | Nacional | pt_BR |
Este item está licenciado na Creative Commons License
![](/themes/Mirage2Novo//images/lume/cc.png)
-
Artigos de Periódicos (39401)Ciências da Saúde (10592)